Related Experiment Video
Updated: May 28, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Plasma Tissue Factor Pathway Inhibitor Levels Correlate with Disease Activity and Are Associated with Altered
Alexander Meyer1, Benno Kohlmaier1, Theresa Bauer1
1Division of General Pediatrics, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, 8036 Graz, Austria.
Abstract:
Background: Patients with inflammatory bowel disease (IBD) exhibit a hypercoagulable state with increased thrombotic risk. Previous studies demonstrated elevated thrombin generation in pediatric IBD, paradoxically accompanied by prolonged lag time during active disease. We hypothesized that elevated tissue factor pathway inhibitor (TFPI) levels during active inflammation contribute to this paradox. Methods: We prospectively enrolled 25 pediatric patients (10 Crohn's disease [CD], 15 ulcerative colitis [UC]) aged 7-18 years with newly diagnosed IBD. Blood samples were collected at diagnosis and in remission. Thrombin generation was assessed using calibrated automated thrombography. Plasma levels of TFPI, tissue factor activity (TFA), vascular endothelial growth factor (VEGF), and interleukin-6 (IL-6) were measured. Results: TFPI levels correlated positively with thrombin generation lag time (r = 0.43, padj < 0.05) and disease activity scores (r = 0.54, padj < 0.05) in patients with active disease (PCDAI/PUCAI > 0). Longitudinal analysis of 16 patients achieving remission revealed elevated TFPI and prolonged lag time during active disease compared to quiescence (both padj < 0.05), while TFA did not change significantly. VEGF decreased significantly upon remission (padj < 0.05), whereas IL-6 showed no significant change. Conclusions: Elevated TFPI levels during active IBD likely contribute to the paradoxical prolongation of thrombin generation lag time. TFPI normalization upon remission reflects vascular inflammation resolution, suggesting TFPI as a potential biomarker and therapeutic target.
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Crohn's Disease
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Clot Retraction and Fibrinolysis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

